Goldman Sachs Suggests Buying Calls on United Therapeutics

Goldman Sachs is out with a research report this morning, where it suggests that traders buy calls on United Therapeutics Corporation UTHR ahead of upcoming data. Goldman Sachs SMid Cap Biotech Analyst, Terence Flynn, is positive on the potential for key Phase 3 data expected this month for a new oral formulation of UTHR's franchise drug Remodulin. The approval of oral Remo would move this drug upstream to 1st/2nd line PAH patients, a $1bn+ market opportunity. If oral Remo is successful in Ph3, the Goldman Sachs analyst sees the potential for shares to trade at $82/share. If Remo fails, he sees the potential for shares to trade at $58/share. Goldman Sachs Suggests buying the July $65.00 call for $6.70. United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients. The company's therapeutic products and product candidates are Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAb) and Glycobiology Antiviral Agents.